SOPHiA GENETICS announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA DDM? Platform. The company will use SOPHiA GENETICS' technology to enhance its solid tumor testing capabilities.

Dhiti Omics specializes in molecular diagnostic and genetic testing. By implementing SOPHiA DDM? for the Agilent SureSelect Cancer CGP application, Dhiti Omics will improve its ability to provide researchers actionable information on mutations and biomarkers across hundreds of genes.

SOPHiA DDM? for SureSelect CGP application combines Agilent's best-in-class genomic profiling assay kit with the SOPHiA DDM? Platform.

Launched in 2023, SureSelect Cancer CGP application offers comprehensive genomic profiling. With the SOPHiA DDM? AI Platform, Dhiti Omics will have an integrated solution for rapid and accurate insights on the basis of the latest guidelines reflecting relevant biomarkers.

The combined efforts of Agilent and SOPHiA GENETICS make it possible for companies like Dhiti Omics to facilitate novel approaches to cancer research and diagnostics.